In 2023, a group of visionary scientists and investors recognized that drug discovery remained an expensive, time-consuming process with high failure rates. Despite advances in AI, the pharmaceutical industry was still struggling to translate computational insights into viable medicines. This realization sparked the creation of Xaira Therapeutics - co-founded and incubated by ARCH Venture Partners and Foresite Labs - to build an integrated biotechnology company that would truly harness the transformative power of artificial intelligence for drug discovery.
Built on the groundbreaking protein design work of Nobel Laureate Dr. David Baker and his team at the University of Washington's Institute for Protein Design, Xaira brings together advanced AI research, expansive data generation, and robust therapeutic product development. The company emerged from stealth mode in 2024 with over $1 billion in funding, ready to revolutionize how we treat disease by making predictions about the right biology to target, the best therapeutics to modulate those targets, and the patients who will benefit most. With offices in South San Francisco, Seattle, and London, Xaira is shifting drug discovery from an empirical science to a precise engineering discipline.
